Nonetheless, it has been shown that KRAS mutations, in addition to EGFR, BRAF and PIK3CA mutations, can act as predictive markers of the response to targeted therapy via the use of EGFR-TKIs in patients with NSCLC [181]. Here, KRAS is linked to non-small cell lung carcinoma.